Background: Paradoxical reactions to benzodiazepines include restlessness, violent behavior, physical assault, act of self-injury and need for restraints. These may occur at variable times after administration. This study was designed to determine the incidence of paradoxical reactions following intravenous midazolam premedication in pediatric patients and to compare the efficacy of extra doses of midazolam with low-dose intravenous ketamine to rapidly tranquillize them.
Methods: A total of 706 ASA I, II children scheduled for elective surgery were given intravenous midazolam premedication. Children who developed a paradoxical reaction were randomly divided into three equal groups to receive: (i) extra midazolam, (ii) ketamine, or (iii) placebo as the test drug for treatment of paradoxical reaction. Ease of rapid tranquillization and need for a rescue tranquillizer (i.e. ketamine; irrespective of patient group) were compared among the three groups.
Results: Twenty-four (3.4%) children developed paradoxical reaction after midazolam premedication. Those who received ketamine as the test drug responded rapidly to ketamine. But the responses of the other two groups to their test drug were poor and the majority of them required ketamine as rescue tranquillizer (six in midazolam, seven in placebo, but no patient in the ketamine group; P < 0.05).
Conclusions: The results of this study demonstrate that ketamine is an effective drug for the treatment of paradoxical reaction following intravenous midazolam premedication. The exact mechanisms of these reactions and how it is aborted by ketamine are not clear.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1460-9592.2004.01349.x | DOI Listing |
Cureus
January 2025
Faculty of Medicine, University of Hama, Hama, SYR.
Paradoxical reactions (PRs) to biologic medications, such as psoriasis, arthritis, and inflammatory bowel disease (IBD), have been increasingly recognized. The aim of reporting this case is to establish an association between golimumab and exacerbation or new (de novo) IBD in patients with axial spondyloarthritis (SpA). Our case involves a young patient with juvenile-onset ankylosing spondylitis (AS) who developed de novo IBD following golimumab therapy for active spinal disease.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by pustules that rapidly progress into ulcers that commonly affect the lower limbs. Recently, successful treatment of PG has been reported with anti-IL 17 treatments. However, there have also been several reports of "paradoxical" induction of new PG lesions after use of IL-17 inhibitors.
View Article and Find Full Text PDFJ Spinal Cord Med
January 2025
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Context: This study aimed to investigate the characteristics, diagnosis, and management of tuberculous longitudinally extensive transverse myelitis (TB-LETM), a rare manifestation of tuberculosis.
Findings: We analyzed two rare cases of TB-LETM and discussed their clinical manifestations and imaging findings in the context of the relevant literature. Patient 1, a 23-year-old female, presented with quadriplegia and dysuria, and spinal magnetic resonance imaging (MRI) revealed lesions extending from C1 to T3.
Cureus
December 2024
Department of Dermatology, Asahikawa Medical University, Asahikawa, JPN.
Eczematous paradoxical reactions are commonly associated with anti-interleukin-17A (anti-IL-17A) antibodies. However, IL-23 p19 inhibitors can also cause similar cutaneous manifestations. We present a case of a 77-year-old Japanese woman with palmoplantar pustulosis (PPP), who developed eczematous lesions on her face, neck, and dorsum of the hands 10 weeks after initiating guselkumab treatment.
View Article and Find Full Text PDFCureus
December 2024
Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Rarely, tumor necrosis factor (TNF)-α inhibitors can paradoxically induce eruptions of psoriasis with generalized pustular psoriasis being among the least common presentations. We report a patient who presented with a generalized pustular eruption following adalimumab therapy for hidradenitis suppurativa (HS). The diagnosis of generalized pustular psoriasis was confirmed with a biopsy showing neutrophilic spongiosis and intraepidermal pustulosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!